BIOXYTRAN, INC 8K

Bioxytran, Inc. reported statistically significant, positive Phase 1b/2a results for its oral antiviral ProLectin-M in mild to moderate COVID-19, with strong Day-5 efficacy at the highest dose and a favorable safety profile.

Bioxytran, Inc. announced positive results from a randomized, double-blind, placebo-controlled Phase 1b/2a clinical trial of its investigational oral antiviral ProLectin-M in 39 hospitalized patients in India with mild to moderate COVID-19, showing that the highest dose (16,800 mg/day) achieved 90% viral clearance and 90% clinical improvement by Day 5 versus 20–40% in lower-dose and placebo groups, with statistically significant earlier viral clearance, favorable safety and tolerability across all dose levels, and no serious adverse events, thereby supporting continued clinical development of this galectin-targeting antiviral as a potential first-line therapy and possibly preventive treatment in future studies.

Filing Facts

CIK

1445815

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-008475

Alert Tier

6